替格瑞洛联合利伐沙班治疗急性冠状动脉综合征临床研究  

Tegrilol Combined with Rivaroxaban for Patients with Acute Coronary Syndrome

作　　者：刘宏颖[1] 李臻[1] LIU Hongying;LI Zhen(Zunhua People′s Hospital,Tangshan,Hebei,China 064200)

机构地区：[1]河北省遵化市人民医院,河北唐山064200

出　　处：《中国药业》2020年第18期55-57,共3页China Pharmaceuticals

基　　金：河北省医学科学研究重点课题[20170784]。

摘　　要：目的探讨替格瑞洛联合利伐沙班治疗急性冠状动脉综合征(ACS)的临床疗效及对患者血小板活化相关因子水平的影响。方法选取医院2017年1月至2019年1月收治的ACS患者130例,按随机数字表法分为对照组和研究组,各65例。两组患者均予常规治疗,研究组患者加服替格瑞洛片及利伐沙班片,均治疗2周。结果研究组总有效率为98.46%,显著高于对照组的84.62%(P<0.05);研究组患者治疗后的白细胞介素17(IL-17)、基质金属蛋白酶-9(MMP-9)、超敏C反应蛋白(hs-CRP)、可溶性细胞黏附分子-1(sICAM-1)、血小板膜糖蛋白GPⅡb/Ⅲa、P-选择素(P-selectin)、血管性血友病因子(vWF)、血管紧张素Ⅱ(AngⅡ)、血浆B型脑钠肽(BNP)水平显著低于对照组,左心室收缩末期内径(LVESd)、左心室舒张末期内径(LVEDd)显著短于对照组,左室射血分数(LVEF)显著高于对照组(P<0.05);研究组与对照组不良反应发生率相当(3.08%比4.62%,P>0.05)。结论替格瑞洛联合利伐沙班治疗ACS,能明显降低血清炎性因子和血小板活化相关因子水平,改善心功能。Objective To investigate the clinical efficacy of tegrilol combined with rivaroxaban for patients with acute coronary syndrome(ACS)and its effect on the level of platelet activation related factors.Methods A total of 130 patients with ACS admitted to the hospital from January 2017 to January 2019 were selected and divided into the control group and study group according to random number table method,65 cases in each group.Both groups received routine treatment,and the study group was added with tegrilol combined with rivaroxaban.Both groups were treated for 2 weeks.Results The total effective rate of the study group was 98.46%,which was significantly higher than 84.62%of the control group(P<0.05).The levels of interleukin 17(IL-17),matrix metalloproteinase-9(MMP-9),high-sensitivity C-reactive protein(hs-CRP),soluble cell adhesion molecule-1(s ICAM-1),platelet membrane glycoprotein GPⅡb/Ⅲa,P-selectin,von Willebrand factor(v WF),angiotensinⅡ(AngⅡ),plasma B-type brain natriuretic peptide(BNP)and left ventricular contraction end systolic diameter(LVESd)and the left ventricular end diastolic diameter(LVEDd)were significantly lower than those of the control group,and the level of left ventricular ejection fraction(LVEF)was significantly higher than that of the control group(P<0.05).The incidence of adverse reactions between the study group and the control group was equivalent(3.08%vs.4.62%,P>0.05).Conclusion Tegrilol combined with rivaroxaban for patients with ACS can significantly reduce the level of serum inflammatory factors and platelet activation related factors and improve cardiac function.

关 键 词：替格瑞洛 利伐沙班 急性冠状动脉综合征 血小板活化因子 心功能 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R973.2[医药卫生—药学]